Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353252 | 0.79 | CYP11B2 (0.64) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL9687758 | 0.79 | CYP11B2 (0.51) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL3385021 | 0.76 | CYP11B2 (0.57) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL1039585 | 0.76 | CYP11B2 (0.67) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL1040360 | 0.75 | CYP11B2 (0.70) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL3381823 | 0.75 | CYP11B2 (0.56) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL14769100 | 0.75 | CYP19A1 (0.73) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL1040367 | 0.74 | CYP11B2 (0.73) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL1041438 | 0.74 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL1041343 | 0.74 | CYP11B2 (1.00) | CYP11B2CYP19A1CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748986-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-1748986-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076794-A1 | Hyperaldosteronism | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20080076794-A1 | Hyperaldosteronism | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20080076794-A1 | Hyperaldosteronism | NOVARTIS AG (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2005118541-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076794-A1 | Hyperaldosteronism | REN, NR3C2, CYP11B2 | CYP11B2 3/4885CHRNB2 1133/4885CHRNA4 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.